In recent years, alternative and complementary medicine including the plant-based drugs with antioxidant and neuroptotective
INTRODUCTION
herbs have shown the ability of plants to synthesize a variety of compounds which interact with biological pathways (1) .
trans-stilbene; C 14 H 12 O 3 , Fig. 1 ), a polyphenolic compound which is found in various plant species, has shown a wide range of pharmacological activities. This phytochemical (nutraceutical) inhibits the cytokines leading to the antiinflammatory and analgesic effects (2). Resveratrol via the induction of apoptosis of cancer cells and metabolism of carcinogens as well as
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inhibition of cancer initiation and progression signalling a well-characterized target of cancers (4), inhibition of this signalling pathway by resveratrol (2) may be implicated in the anticarcinogenic effects of this natural polyphenol. Regarding the cardiometabolic protection, resveratrol inhibits inducible nitric oxide synthase (iNOS) and platelets aggregation, elevates high-density lipoprotein, and reduces low-density lipoprotein, trigycerides, and reactive oxygen species (ROS) accumulation (5). Resveratrol acts against the oxidative stress via the up-regulation of antioxidant enzymes synthesis and enhancement of the anti-oxidant capacity, free radical scavenging activity, as well as the inhibition of lipid because of its complexity and multi-factorial nature, has remained as a challenging medical problem (7) . Resveratrol by inhibition of the adipogenesis and down-regulation of lipogenic genes, and enhancement of fat oxidation has shown promising anti-obesity effects (8) . In type 2 diabetes mellitus, resveratrol, by activating sirtuin 1, elevates the glucose uptake Regarding the neuroprotective properties of resveratrol, there are reports indicating its inhibitory effects against the in the hippocampus. Resveratrol improves the sensorimotor function, modulates the cholinergic neurotransmission, and prevents the oxidative damage of astroglial cells and cognitive decline. This natural compound downregulates the glutamateinduced extracellular signal-regulated kinase activation and interleukin-1 Study on the primary cortical neuron cultures has revealed that resveratrol through the inhibition of intracellular calcium increase and production of ROS exerts the protective effect against N-Methyl-D-aspartate-induced neuronal death (13). Furthermore, this natural polyphenol by antioxidant activities protects the hippocampal neurons against the NO-induced toxicity (14). In Alzheimer's disease, resveratrol has been shown to NO production, iNOS expression, prostaglandin E 2 accumulation, and NF-B translocation (15). Resveratrol exhibits therapeutic potential in other neurodegenerative diseases such as Parkinson's disease (16) and amyotrophic lateral sclerosis properties. This polyphenolic compound prevents the spinal cord and brain damage following the ischemia-reperfusion or traumatic injury (18).
In recent years, it has been shown that resveratrol exerts antidepressant effects via the modulation of hypothalamicpituitary (HPA) axis activity and oxidative-nitrosative stress (19-21). Based on an increasing evidence, neurotrophins, a protein family including the nerve growth factor (NGF), brain-derived neurotrophic fac tor (BDNF), neurotrophin 3 (NT-3), NT-4/5, and NT-6 act as the potential mediators of antidepressant responses (22, 23). Neurotrophins mediate their effects by the ligation of two major types of receptors: a pan-neurotrophin receptor (p75 N TR ), thus trigger a number of cel lular responses including the long-term trophic effects as well as the rapid chemo tropic and morphogenetic actions on the developing neurons, synaptic transmission, and neuronal excitability (24-27). Neurotrophins are also implicated in the neuronal plasticity and exhibit neuroprotective effects that disorders (28). Indeed, dysfunction of the neurotrophin-related signalling mechanisms is involved in the pathogenesis of a number of psychiatric disorders (23-26). The prototypical neurotrophin, NGF, which regulates the stress and cognitive function (29,30) and mediates the action of a wide variety of psychotropic agents (31-35), along with the eCBs which regulates the neuroprotective processes (36) , are implicated in the mechanism of action of resveratrol (37) that will be discussed herein.
RESEVERATROL AND NGF
Following the discovery of the first neurotrophin, NGF, by the Nobel Laureate Rita Levi-Montalcini (38), further Resveratrol, NGF, and endocannabinoids studies showed that NGF as well as other neurotrophins (e.g. BDNF) affect the neuronal survival and differentiation, exerts a regulatory role in the memory and attention tasks, in neuroendocrine-immune interaction, and neurological disorders (39, 41) . Be cause of its antioxidant, angiogenic and metabotrophic (including insulinotropic) prop erties, NGF is implicated in the molecular mechanisms of cardiometabolic diseases (41, 42, 48 and references therein), accelerates corneal and skin wound healing (43, 44) and plays a fundamental role in tissue engineering (45) . Over the last decade, it has been suggested that electroconvulsive treatment or antidepressant drugs may act by increasing neurotrophin contents in the cen tral nervous system (CNS). Based on the ability of NGF to induce the release of hypothalamic vasopressin which plays a crucial role in the formation of social bonding (46) , it was suggested that NGF by modulating the neuroendocrine functions is implicated in the molecular mechanisms of emotions. In this respect, the involvement of NGF and BDNF in the pathogenesis of neuropsychiatric disorders (39, 41, (47) (48) (49) and in the mechanisms of action of a wide range of psychotropic agents (31-35, 41, 50) were reported. management of neuropsychiatric disorders. Recently, the involvement of NGF in the mech anism of action of resveratrol has also been reported (37) . The elevation of brain NGF levels following chronic treatment with resveratrol indicates that the neurotrophic effect is a slow-developing process. The sustained enhancement of NGF protein contents in the brain regions which regulate the emotional activity may be considered as a mechanism by which resveratrol exerts its therapeutic effects in the neuropsychiatric disorders. Since NGF exerts the stimulatory effect on the cell proliferation (51), therefore, the elevation of frontal cortex NGF following the chronic administration of resveratrol might be of therapeutic significance against the stress-induced reduction in cell proliferation in the frontal cortex (52).
Resveratrol also elevates NGF level in the hippocampus (37) . It is noteworthy that NGF plays a pivotal role in learning, hippocampal plasticity, and neurogenesis (29, 30), and induces acetylcholine release in the hippocampus (49) leading to the improved cognitive performance. Therefore, resveratrol by enhancement of the hippocampal NGF may stimulate the hippocampal neurogenesis and improve the cognitive function. Moreover, this nutraceutical increases NGF contents in the olfactory bulb and amygdala (37) . The critical role of NGF in the development, regeneration, and mainte nance of the olfactory system of mammals has been well-documented (29, 30, 53) . NGF also facilitates the cholinergic neurotransmis sion between the amygdala and nucleus basalis (54) leading to the improvement of cognitive function. Altogether, it appears that elevation of brain NGF, also BDNF, contents constitutes a major part of the biochemical altera tions induced by certain psychotropic agents (31-35, 41, 50) including resveratrol (37) .
RESVERATROL AND THE ENDOCANNABINOID SIGNALING
Over the last decade, the eCBs, a group of neuromodulatory lipids and their receptors which regulates the neuronal proliferation and maturation (55) , synaptic plasticity (56), emotional reactivity (57), neurotensin neurotransmission (58-59) and neurotrophin signalling (60, 61) , has emerged as a topic of great interest in neuroscience and pharmacology. The endocan nabinoids, anandamide and 2-ara chidonoylglycerol (2-AG), are produced on-demand by the lipid precursors in the neuronal cell membrane and activate two types of G protein-coupled receptors, cannabinoid CB 1 and CB 2 , leading to a wide variety of pathological and physiological processes. The eCBs exerts neuroremodulatory action in various types of diseases (62) . In this context, development of anandamide uptake blockers, cannabinoid receptor agonists, and selective inhibitors of endocannabinoid degradation has been the focus of intense research (63, 64) . In transsynaptic neuronal changes due to the neurodegenerative processes (65), microglia-induced neurotoxicity, and cytotoxicity induced by the excitatory amino acids (66), the eCBs exerts protective effects (67) . In general, the endocannabinoids exert their neuroprotective effects through a variety of mechanisms and/or glutamate release, and activation of antioxidative mechanisms. Furthermore, activation of the CB 1 receptors leads to the stimulation of phosphoinositide 3-kinase (PI3-K)/ AKT signalling pathway and promotion of the cell survival (68) . According to the protective effects of the eCBs against the excitotoxic damage and neuronal insult (58, 67) , this ubiquitous signalling system might be an emerging target for the therapeutic interventions against the neurological disorders. In Parkinson's disease (PD), the most prevalent neurodegenerative disorder affecting the basal ganglia, dopamine depletion results in a cascade of neurochemical events within the basal ganglia. Endocannabinoids and their synthesizing and degrading enzymes are abundantly found in the basal ganglia (69) . Indeed, the striatal eCBs undergoes a profound neurophysiological alteration in order Hassanzadeh, Atyabi and Dinarvand to restore the homeostasis within the basal ganglia (70) . In Huntington's disease, the CB 1 receptor agonists and inhibitors of eCB transport reduce the hyperkinesia associated with the disease (71) . Stimulation of the CB 1 or CB 2 receptors in multiple sclerosis (72) . Furthermore, CB 1 agonists promote the oligodendrocyte survival and mRNA expression of myelin protein (73) suggesting that the eCBs not only attenuates the symptoms of the disease, but also improves the function of oligodendrocytes effects. In the spinal cord injury, a cascade of cellular and molecular events which occur following the initial damage, is a main target for therapeutic interventions including the application of cannabinoids. In an animal model of the spinal cord injury, reported (74) suggesting that activation of the eCBs is a part of the neuroprotective response which is triggered following the injury.
In epilepsy, the imbalance between the inhibitory and excitatory neural circuits leads to the excitotoxicity and neuronal death (75) (76) (77) . Based on the regulatory effects of the eCBs on the inhibitory and excitatory transmissions and the enhancement of the eCB contents in epilepsy (78) , this ubiquitous signalling system may be a promising target for antiepileptic therapies. In ischemic stroke, recombinant tissue plasminogen activator improves the functional outcome in patients, however, it should be administered within a short period of time following the onset of symptoms. The nonpsychoactive component of cannabis, cannabidiol, has been shown to inhibit the voltage-sensitive Ca 2+ channels leading to the reduction of excitotoxicity. Administration of cannabidiol 6 h after the cerebral ischemia has led to the neuroprotective effects. Furthermore, cannabidiol has preserved the regional at 3 days after the cerebral ischemia (79) indicating its longlasting preventive effects on the post-ischemic cerebrovascular events.
In Alzheimer's disease which is associated with neuro-- (62, 81) . may exert protective effects through the inhibition of NO release and activation of mitogen-activated protein kinase pathway (82) . In amyotrophic lateral sclerosis, one of most the debilitating neurodegenerative disorder which is characterised by the degeneration of motor neurons, the eCBs has shown antiexcitotoxic damage and preservation of glutamate homeostasis (83) . Following the of the endocannabinoid binding sites in substan tia gelatinosa, analgesic effects of the eCBs in both acute and chronic pain (84, 85) . The interaction between the opioid signalling and eCBs is also well-documented (86) . Based on these multitarget bioactivities of the eCBs, its potential implication in the mechanism through which resveratrol regulates brain NGF contents has been investigated. It has been found that resveratrol affects brain NGF levels under the regulatory drive of CB 1 receptors (37). Furthermore, the brain eCB contents are increased following the chronic treatment with resveratrol (37) . It appears that the eCBs activation is required, at least in part, for the neuroprotective actions of resveratrol against the various types of neurological disorders.
Regarding the mood disorders, compounds which affect the eCBs function have been shown to regulate the monoaminemediated neurotransmission and activity of HPA axis (87) . In the limbic brain regions where the neuronal activity is altered in depression (88), endocannabinoids are found at moderate to high levels (87) . Indeed, the regulatory role of the eCB enhancers on mood (57), has opened a new line of research in antide pressant drug discovery and development of novel anxiety-related disorders as the CB 1 receptor antagonist, SR141716A, has been shown to induce anxiety-like responses (89) . Chronic exposure to a wide range of psychotropic agents the brain regions which regulate the synaptic plasticity and emotional behaviour (32) (33) (34) (35) 37) . In fact, the brain regional distribu tion of endocannabinoids following the administration of psychotropic agents represents the important role of the eCBs in the development of effective coping strategies to the emotional responses. As recently reported, four-week oncedaily injections of resveratrol results in a sustained elevation of annadamide and 2-AG contents in the brain regions implicated in the modulation of emotional behaviour and an intrinsic eCB tone which is involved in the mechanism of action of resveratrol.
Following chronic administration of resveratrol, NGF and endocannabinoids have been increased in the same brain regions suggesting that the regulatory effect of resveratrol Resveratrol, NGF, and endocannabinoids on brain NGF contents depends on the coordinated release of endocannabinoids. It appears that a balance between NGF and eCB signalling mediates the pharmacological effects of this natural polypheonlic compound. In addition to its intrinsic radical scavenging activity, resveratrol reduces the production expression of iNOS gene. This natural polyphenol upregulates the activities of protein kinase C and heme oxygenase leading to the neuroprotective effects. In fact, multiple intracellular signalling pathways and molecular targets are involved in the mechanism of action of resveratrol (90) . Involvement of the extracellular signal-regulated kinase cascade, noradrenaline and serotonin system, and HPA axis in the antidepressantlike effects of resveratrol has been previously demonstrated eCBs are also implicated in the mechanism of action of resveratrol. In this context, resveratrol by affecting NGF and of diseases which are associated with abnormal NGF or eCBs. Resveratrol enhances the brain NGF contents under the regulatory drive of CB 1 receptors indicating the importance of the endogenous cannabinoid activity in the neurotrphic action of this nutraceutical.
In recent years, smart delivery of drugs, neurotrophins, and nutrients has been the focus of intense research. In nanotechnology-based approaches, nanoencapsulation of nutraceuticals, application of nanosensors and computational modelling have been the emerging topics (93) (94) (95) (96) (97) . In this respect, designing the nanoformulations of resveratrol has led to the increased cellular uptake and improved bioavailability potential side effects of this nutraceutical which has shown multi-spectrum therapeutic applications.
CONCLUSION
For over a decade, natural products with antioxidant, antiinflammatory, metabotrophic and neuroptotective effects have been the focus of intense research. Resveratrol, a naturally occurring polyphenolic compound, has shown multi-spectrum therapeutic applications. Besides its therapeutic potential in ischemia, cancer, diabetes, and cardiometabolic disorders, resveratrol has proved to be a promising therapeutic agent against the neurodegenerative disorders. In recent years, functions of the eCBs has resulted in a better understanding of the pathological processes which occur in the CNS. 
